Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004

Lancet Infectious Diseases

Volumn 5, Issue 12, 2005, Pages 763-774

  Olliaro, Piero L ^a,b   Guerin, Philippe J ^c,d   Gerstl, Sibylle ^d   Haaskjold, Astrid Aga ^e   Rottingen, John Arne ^f,g   Sundar, Shyam ^h  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d EPICENTRE   (France)

^e UNIVERSITY OF OSLO   (Norway)

^f Norwegian Health Services Research Centre   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

^h BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; GAMMA INTERFERON; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; UREA STIBAMATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; BACKACHE; BANGLADESH; CHILL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYANOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEVER; GASTROINTESTINAL TOXICITY; GLOMERULONEPHRITIS; HEALTH CARE; HOUSEHOLD; HUMAN; HYPOKALEMIA; INDIA; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; METHEMOGLOBINEMIA; MORTALITY; MYOCARDITIS; NEPAL; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RIGOR; SHOCK; SIDE EFFECT; THROMBOPHLEBITIS; TOXICITY; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CHILD; CLINICAL TRIALS; DRUG RESISTANCE; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 28044469320     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70296-6     Document Type: Review

References (76)

1. WHO The World Health Report 2000 2000 WHO Geneva
2. BL Herwaldt Leishmaniasis Lancet 354 1999 1191 1199
3. CP Thakur Socio-economics of visceral leishmaniasis in Bihar (India) Trans R Soc Trop Med Hyg 94 2000 156 157
4. S Sundar, DK More, MK Singh Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic Clin Infect Dis 31 2000 1104 1107
5. S Sundar Drug resistance in Indian visceral leishmaniasis Trop Med Int Health 6 2001 849 854
6. RN Davidson Practical guide for the treatment of leishmaniasis Drugs 56 1998 1009 1018
7. HW Murray Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches Int J Infect Dis 4 2000 158 177
8. PJ Guerin, P Olliaro, S Sundar Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda Lancet Infect Dis 2 2002 494 501
9. WHO/TDR Press release: Elimination of kala-azar from endemic countries in the south-east Asia region. Health ministers sign memorandum of understanding. Geneva/New Delhi http://www.who.int/tdr/diseases/leish/press_release.htm May 18, 2005 (accessed Sept 29, 2005)
10. G Chatellier, E Zapletal, D Lemaitre, J Menard, P Degoulet The number needed to treat: a clinically useful monogram in its proper context BMJ 312 1996 426 429
11. DG Altman, PK Andersen Calculating the number needed to treat for trials where the outcome is time to an event BMJ 319 1999 1492 1495
12. TK Jha, P Olliaro, CP Thakur Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India BMJ 316 1998 1200 1205
13. S Sundar, VP Singh, S Sharma, MK Makharia, HW Murray Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis J Infect Dis 176 1997 1117 1119
14. CP Thakur, TP Kanyok, AK Pandey A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis Trans R Soc Trop Med Hyg 94 2000 429 431
15. CP Thakur, TP Kanyok, AK Pandey Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study Trans R Soc Trop Med Hyg 94 2000 432 433
16. CP Thakur, GP Sinha, AK Pandey Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases Ann Trop Med Parasitol 92 1998 561 569
17. CP Thakur, S Narayan A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis Ann Trop Med Parasitol 98 2004 129 138
18. S Sundar, TK Jha, CP Thakur Oral miltefosine for Indian visceral leishmaniasis N Engl J Med 347 2002 1739 1746
19. CP Thakur, GP Sinha, AK Pandey, D Barat, PK Sinha Amphotericin B in resistant kala-azar in Bihar Natl Med J India 6 1993 57 60
20. S Sundar, H Mehta, AV Suresh Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations Clin Infect Dis 38 2004 377 383
21. S Sundar, LB Gupta, V Rastogi, G Agrawal, HW Murray Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis Trans R Soc Trop Med Hyg 94 2000 200 204
22. S Sundar, NK Agrawal, PR Sinha, GS Horwith, HW Murray Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony Ann Intern Med 127 1997 133 137
23. S Sundar, AK Goyal, AK Mandal Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis J Assoc Physicians India 47 1999 186 188
24. S Sundar, G Agrawal, M Rai, MK Makharia, HW Murray Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial BMJ 323 2001 419 422
25. S Sundar, TK Jha, CP Thakur Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study Clin Infect Dis 37 2003 800 804
26. CP Thakur, AK Pandey, GP Sinha Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study Trans R Soc Trop Med Hyg 90 1996 319 322
27. AD Bryceson Therapy in man W Peters R Killick-Kendrick The leishmaniasis in biology and medicine 1987 Academic Press London 848 903
28. S Sundar, F Rosenkaimer, ML Lesser, HW Murray Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis J Infect Dis 171 1995 992 996
29. CP Thakur, M Kumar, P Kumar, BN Mishra, AK Pandey Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study Br Med J (Clin Res Ed) 296 1988 1557 1561
30. CP Thakur, M Kumar, SK Singh Comparison of regimens of treatment with sodium stibogluconate in kala-azar BMJ 288 1984 895 897
31. CP Thakur, M Kumar, AK Pandey Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate Indian J Med Res 93 1991 103 110
32. M Mishra, UK Biswas, AM Jha, AB Khan Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar Lancet 344 1994 1599 1600
33. CP Thakur, GP Sinha, V Sharma Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar Indian J Med Res 97 1993 170 175
34. CP Thakur A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study Int J Antimicrob Agents 17 2001 67 70
35. CP Thakur, S Narayan, A Ranjan Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India Indian J Med Res 120 2004 166 172
36. M Mishra, MP Singh, D Choudhury, VP Singh, AB Khan Amphotericin B for second-line treatment of Indian kala-azar Lancet 337 1991 926
37. M Mishra, UK Biswas, DN Jha, AB Khan Amphotericin versus pentamidine in antimony-unresponsive kala-azar Lancet 340 1992 1256 1257
38. TK Jha, YN Giri, TK Singh, S Jha Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India Am J Trop Med Hyg 52 1995 536 538
39. CP Thakur, GP Sinha, AK Pandey, D Barat, RK Singh Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison Bull World Health Organ 72 1994 931 936
40. CP Thakur, GP Sinha, D Barat, RK Singh Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Ann Trop Med Parasitol 88 1994 365 370
41. OP Giri Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B J Assoc Physicians India 42 1994 688 689
42. OP Giri, AN Singh Experience with amphotericin B in sodium stibogluconate-unresponsive cases of visceral leishmaniasis in north Bihar J Assoc Physicians India 42 1994 690 691
43. CP Thakur, GP Sinha, AK Pandey Comparison of regimens of amphotericin B deoxycholate in kala-azar Indian J Med Res 103 1996 259 263
44. CP Thakur, P Kumar, N Kumar A randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar J Assoc Physicians India 46 1998 779 783
45. CP Thakur, RK Singh, SM Hassan Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases Trans R Soc Trop Med Hyg 93 1999 319 323
46. CP Thakur, S Ahmed Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India Indian J Med Res 113 2001 14 18
47. S Sundar, TK Jha, CP Thakur Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study Am J Trop Med Hyg 66 2002 143 146
48. PV Bodhe, RN Kotwani, BG Kirodian Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis Trans R Soc Trop Med Hyg 93 1999 314 318
49. S Sundar, HW Murray Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex J Infect Dis 173 1996 762 765
50. S Sundar, AK Goyal, DK More, MK Singh, HW Murray Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex Ann Trop Med Parasitol 92 1998 755 764
51. CP Thakur Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar Trans R Soc Trop Med Hyg 88 1994 698 699
52. TK Jha Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India Trans R Soc Trop Med Hyg 77 1983 167 170
53. CP Thakur Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis) Trans R Soc Trop Med Hyg 78 1984 391 398
54. SN Jha, NK Singh, TK Jha Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial J Assoc Physicians India 39 1991 314 316
55. CP Thakur, M Kumar, AK Pandey Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study Am J Trop Med Hyg 45 1991 435 441
56. VN Das, A Ranjan, AN Sinha A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis J Assoc Physicians India 49 2001 609 613
57. TK Jha, VK Sharma Pentamidine-induced diabetes mellitus Trans R Soc Trop Med Hyg 78 1984 252 253
58. CP Thakur, P Olliaro, S Gothoskar Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin)-antimonial combinations, a pilot study in Bihar, India Trans R Soc Trop Med Hyg 86 1992 615 616
59. CP Thakur, S Bhowmick, L Dolfi, P Olliaro Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial Trans R Soc Trop Med Hyg 89 1995 219 223
60. S Sundar, F Rosenkaimer, MK Makharia Trial of oral miltefosine for visceral leishmaniasis Lancet 352 1998 1821 1823
61. S Sundar, LB Gupta, MK Makharia Oral treatment of visceral leishmaniasis with miltefosine Ann Trop Med Parasitol 93 1999 589 597
62. TK Jha, S Sundar, CP Thakur Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis N Engl J Med 341 1999 1795 1800
63. S Sundar, A Makharia, DK More Short-course of oral miltefosine for treatment of visceral leishmaniasis Clin Infect Dis 31 2000 1110 1113
64. S Sundar, TK Jha, H Sindermann Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis Pediatr Infect Dis J 22 2003 434 438
65. SK Bhattacharya, TK Jha, S Sundar Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India Clin Infect Dis 38 2004 217 221
66. R Dietze, SF Carvalho, LC Valli Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi Am J Trop Med Hyg 65 2001 685 689
67. R Lira, S Sundar, A Makharia Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani J Infect Dis 180 1999 564 567
68. E Moore, D O'Flaherty, H Heuvelmans Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya Bull World Health Organ 79 2001 388 393
69. K Ritmeijer, H Veeken, Y Melaku Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome Trans R Soc Trop Med Hyg 95 2001 668 672
70. H Veeken, K Ritmeijer, J Seaman, R Davidson A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan Trop Med Int Health 5 2000 312 317
71. S Sundar, PR Sinha, NK Agrawal A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate Am J Trop Med Hyg 59 1998 139 143
72. S Rijal, F Chappuis, R Singh Sodium stibogluconate cardiotoxicity and safety of generics Trans R Soc Trop Med Hyg 97 2003 597 598
73. S Sundar, BB Thakur, AK Tandon Clinicoepidemiological study of drug resistance in Indian kala-azar BMJ 308 1994 307
74. S Sundar, HW Murray Availability of miltefosine for the treatment of kala-azar in India Bull World Health Organ 83 2005 394 395
75. K Seifert, S Matu, F Javier Perez-Victoria Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine) Int J Antimicrob Agents 22 2003 380 387
76. A Bryceson A policy for leishmaniasis with respect to the prevention and control of drug resistance Trop Med Int Health 6 2001 928 934